CJC-1295 vs Ipamorelin

A synthetic GHRH analogue that stimulates pituitary growth hormone release. The short-acting form (no DAC) is typically paired with a ghrelin agonist like ipamorelin.

A selective growth hormone secretagogue that stimulates pulsatile GH release from the pituitary without significantly affecting cortisol, prolactin, or appetite.

CJC-1295 is a modified fragment of growth-hormone releasing hormone (residues 1–29) with four amino-acid substitutions that extend its half-life. The "no DAC" variant lacks the drug affinity complex tag and therefore has a shorter duration, producing physiological GH pulses.

Ipamorelin binds the ghrelin receptor (GHSR-1a) in the pituitary, triggering growth hormone release. Unlike earlier secretagogues such as GHRP-6, ipamorelin is highly selective and does not induce hunger or stimulate cortisol.

100–200 mcg, 1–3 times daily (research protocols)

200–300 mcg, 1–3 times daily (research protocols)

~30 minutes (no DAC); ~7 days (with DAC)

~2 hours

Subcutaneous

Subcutaneous

research-only

research-only

£22 · £11/mg via Peptides UK

£21 · £4.2/mg via Peptides UK